Brucellosis Vaccines Market Size to Surpass USD 389.50 Mn by 2033

Prathamesh

1 month ago

The global brucellosis vaccines market size surpassed USD 242.70 million in 2023 and is anticipated to be worth around USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.

Key Points

The North America brucellosis vaccines market size reached USD 104.36 million in 2023 and is expected to surpass around USD 167.49 million by 2033.
North America has dominated the market with revenue share of 43% in 2023.
By application, in 2023, the cattle segment has accounted 57% revenue share in 2023.
By type, the RB51 vaccine segment dominated the market with revenue share of 43% in 2023.
By Vaccine Type, the DNA Vaccines segment has captured 32.5% revenue share in 2023.
By distribution channel, the public segment had the largest market share in 2023.

Brucellosis Vaccines Market Size 2024 to 2033

Brucellosis is a bacterial infection that affects both animals and humans, primarily caused by Brucella species. The disease can lead to serious complications in livestock, impacting the agricultural industry. The global market for brucellosis vaccines is driven by the need to control the spread of the disease in both animals and humans. Brucellosis vaccines are essential for preventing the infection in livestock and, consequently, reducing the risk of transmission to humans. The market encompasses a variety of vaccine types and products designed for different species of animals.

Get a Sample: https://www.precedenceresearch.com/sample/4113

List of Contents

Toggle

Growth Factors:

The growth of the brucellosis vaccines market is driven by several factors. First, increasing awareness about the impact of brucellosis on animal and human health has led to greater demand for vaccines. Moreover, the growth of the livestock industry and the rising need to protect livestock from diseases also fuel the market. Government initiatives and regulations aimed at controlling brucellosis outbreaks contribute to market growth. Additionally, advancements in vaccine technology and research into more effective vaccines are expected to support market expansion.

Region Insights: The brucellosis vaccines market varies across different regions due to differences in agricultural practices, government regulations, and the prevalence of brucellosis. Regions with large livestock populations, such as North America, Europe, and Asia-Pacific, are key markets for brucellosis vaccines. In these regions, strong government support for disease control measures and awareness campaigns drive market growth. Emerging markets in Latin America and Africa also offer potential for growth as governments implement measures to control the spread of brucellosis.

Brucellosis Vaccines Market Scope

Report Coverage	Details
Global Market Size in 2023	USD 242.70 Million
Global Market Size in 2024	USD 254.46 Million
Global Market Size by 2033	USD 389.50 Million
Growth Rate from 2024 to 2033	CAGR of 4.84%
Largest Market	North America
Base Year	2023
Forecast Period	2024 to 2033
Segments Covered	By Type, By Vaccine, By Application, and By Distribution Channel
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Brucellosis Vaccines Market Dynamics

Drivers:

The main drivers of the brucellosis vaccines market include the increasing prevalence of brucellosis in livestock, which leads to demand for vaccines to control the disease. Government regulations and initiatives to prevent the spread of brucellosis also play a key role in market growth. Additionally, the economic impact of brucellosis on the agricultural industry motivates investments in vaccines.

Opportunities

Opportunities in the brucellosis vaccines market include the development of more effective and affordable vaccines. Innovations such as DNA vaccines and other advanced vaccine technologies present potential for growth. Moreover, partnerships between governments, research institutions, and pharmaceutical companies could lead to new breakthroughs in vaccine development. Expanding market access to underdeveloped regions with high brucellosis prevalence also offers growth potential.

Challenges:

The market faces several challenges, such as the complexity of brucellosis as a disease and the difficulties in developing effective vaccines. There are also regulatory hurdles and safety concerns associated with the use of vaccines in different species. In some regions, limited awareness and access to vaccines may hinder market growth. Additionally, the potential for side effects and the need for booster shots could impact the acceptance of vaccines among livestock owners.

Brucellosis Vaccines Market Recent Developments

In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.